Overview

Sorafenib tosylate is a multi-kinase inhibitor that targets RAF (including BRAF), VEGFR and PDGFR signaling pathways, and it is supplied as 200 mg film-coated tablets in a 60-tablet pack. For B2B buyers operating in the oncology distribution chain, the commercial conversation is less about pharmacology and more about reliability: can a supplier deliver a correctly documented, consistently available product that meets pharmacopeial standards across repeated procurement cycles? This article outlines the sourcing factors that matter most when procuring sorafenib tosylate tablets for institutional or wholesale channels.

Documentation and Quality Verification

Every procurement batch should arrive with a current Certificate of Analysis (CoA), a valid Good Manufacturing Practice (GMP) certificate, and, where the market requires it, a Certificate of Pharmaceutical Product (CPP) or marketing authorization reference. Buyers should confirm the stated strength (200 mg sorafenib tosylate per tablet), the pack size, and the manufacturer identity against the CoA. Retaining batch-level documentation supports traceability and simplifies any later quality investigation, which is especially important for a long-marketed oral oncology agent with multiple global manufacturers.

Storage and Cold-Chain Realities

Sorafenib tablets are stored at controlled room temperature (generally below 30°C) and protected from moisture; the product does not require refrigerated transport. That distinction matters for logistics budgeting, because a room-temperature-stable oral oncology agent avoids the cost and handling burden of an active cold chain. Even so, buyers should specify desiccant packaging and moisture-barrier secondary packaging for humid transit corridors, since film-coated tablets remain sensitive to absorbed water over long shipping windows.

Supply Continuity for Chronic Use

Because sorafenib is used as a continuous, long-term oral therapy, intermittent stockouts carry real consequences for end patients. Procurement teams should evaluate a supplier's track record on lead time, minimum order quantity (MOQ), and the stability of the active pharmaceutical ingredient (API) source. Where multiple approved manufacturers exist, qualifying a second source reduces single-supplier risk without compromising the documented specification, and it provides negotiating leverage on both price and delivery certainty.

FAQ

Q: Does sorafenib tosylate require cold-chain shipping? A: No. The tablets are stored at controlled room temperature below 30°C and protected from moisture, so refrigerated logistics are not required, though moisture-barrier packaging is recommended for humid routes.

Q: What documents should accompany each batch? A: At minimum a Certificate of Analysis, a current GMP certificate, and market-required authorization references such as a CPP, with batch numbers traceable to the named manufacturer.

Q: Why is dual-source qualification useful for sorafenib? A: As a continuous long-term therapy, supply interruptions affect patient access; qualifying a second approved manufacturer reduces single-supplier risk while preserving the documented specification.

Q: What strength and pack configuration are commonly sourced? A: The 200 mg tablet strength in a 60-tablet pack is the standard commercial configuration referenced for this product.